Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 2/20 | 0.58 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15936058 | 0.86 | AKR1C2 (0.58) | AKR1C2AKR1C1TSHRPTGS1PTGS2 | |
| SCHEMBL9202628 | 0.85 | ADRA1D (0.48) | AKR1C2AKR1C1TSHRPTGS1PTGS2 | |
| SCHEMBL1355668 | 0.84 | AKR1C2 (0.51) | AKR1C2AKR1C1TSHRPTGS1PTGS2 | |
| SCHEMBL28817579 | 0.83 | AKR1C2 (0.46) | AKR1C2AKR1C1TSHRPTGS1PTGS2 | |
| SCHEMBL10606717 | 0.82 | AKR1C2 (0.43) | AKR1C2AKR1C1TSHRCASP1SMN1; SMN2 | |
| SCHEMBL10159905 | 0.81 | AKR1C2 (0.49) | AKR1C2AKR1C1TSHRNR1H4PTGS1 | |
| SCHEMBL4961760 | 0.81 | PPARA (0.55) | AKR1C2AKR1C1TSHRPTGS1PTGS2 | |
| SCHEMBL11984397 | 0.80 | SMN1; SMN2 (0.57) | AKR1C2AKR1C1TSHRCASP1SMN1; SMN2 | |
| SCHEMBL31000559 | 0.80 | SLC7A5 (0.57) | TSHRCASP1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL9558139 | 0.80 | TSHR (0.61) | TSHRCASP1SMN1; SMN2NR1H4MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | AKR1C2 2661/4885AKR1C1 2642/4885TSHR 4659/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | AKR1C2 2661/4885AKR1C1 2642/4885TSHR 4659/4885 |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | AKR1C2 2661/4885AKR1C1 2642/4885TSHR 4659/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | AKR1C2 2661/4885AKR1C1 2642/4885TSHR 4659/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | AKR1C2 2661/4885AKR1C1 2642/4885TSHR 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.